These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 10454453

  • 1. Differential effects of T- and L-type calcium antagonists on glomerular dynamics in spontaneously hypertensive rats.
    Nakamura Y, Ono H, Frohlich ED.
    Hypertension; 1999 Aug; 34(2):273-8. PubMed ID: 10454453
    [Abstract] [Full Text] [Related]

  • 2. N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model.
    Zhou X, Ono H, Ono Y, Frohlich ED.
    J Hypertens; 2002 May; 20(5):993-1000. PubMed ID: 12011661
    [Abstract] [Full Text] [Related]

  • 3. ACE inhibition prevents and reverses L-NAME-exacerbated nephrosclerosis in spontaneously hypertensive rats.
    Ono H, Ono Y, Frohlich ED.
    Hypertension; 1996 Feb; 27(2):176-83. PubMed ID: 8567038
    [Abstract] [Full Text] [Related]

  • 4. Renoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with and without L-NAME.
    Francischetti A, Ono H, Frohlich ED.
    Hypertension; 1998 Mar; 31(3):795-801. PubMed ID: 9495263
    [Abstract] [Full Text] [Related]

  • 5. Contrasting effects of selective T- and L-type calcium channel blockade on glomerular damage in DOCA hypertensive rats.
    Karam H, Clozel JP, Bruneval P, Gonzalez MF, Ménard J.
    Hypertension; 1999 Oct; 34(4 Pt 1):673-8. PubMed ID: 10523345
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin type 1 receptor antagonism and ACE inhibition produce similar renoprotection in N(omega)-nitro-L>-arginine methyl ester/spontaneously hypertensive rats.
    Nakamura Y, Ono H, Zhou X, Frohlich ED.
    Hypertension; 2001 May; 37(5):1262-7. PubMed ID: 11358938
    [Abstract] [Full Text] [Related]

  • 7. Superiority of combination of thiazide with angiotensin-converting enzyme inhibitor or AT1-receptor blocker over thiazide alone on renoprotection in L-NAME/SHR.
    Zhou X, Matavelli LC, Ono H, Frohlich ED.
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F871-9. PubMed ID: 15900021
    [Abstract] [Full Text] [Related]

  • 8. Hydrochlorothiazide exacerbates nitric oxide-blockade nephrosclerosis with glomerular hypertension in spontaneously hypertensive rats.
    Ono Y, Ono H, Frohlich ED.
    J Hypertens; 1996 Jul; 14(7):823-8. PubMed ID: 8818920
    [Abstract] [Full Text] [Related]

  • 9. Different effects of calcium antagonists on fluid filtration of large arteries and albumin permeability in spontaneously hypertensive rats.
    Lacolley P, Poitevin P, Koen R, Levy BI.
    J Hypertens; 1998 Mar; 16(3):349-55. PubMed ID: 9557928
    [Abstract] [Full Text] [Related]

  • 10. Effect of the novel T-selective calcium channel antagonist mibefradil on kidney function in comparison with amlodipine.
    Greven J.
    Arzneimittelforschung; 1998 Aug; 48(8):806-10. PubMed ID: 9748707
    [Abstract] [Full Text] [Related]

  • 11. Mibefradil prevents L-NAME-exacerbated nephrosclerosis in spontaneously hypertensive rats.
    Qiu C, Bruneval P, Roeckel A, Heudes D, Duong Van Huyen JP, Roux S.
    J Hypertens; 1999 Oct; 17(10):1489-95. PubMed ID: 10526911
    [Abstract] [Full Text] [Related]

  • 12. Role of protein kinase C in Ca channel blocker-induced renal arteriolar dilation in spontaneously hypertensive rats--studies in the isolated perfused hydronephrotic kidney.
    Hayashi K, Wakino S, Ozawa Y, Homma K, Kanda T, Okubo K, Takamatsu I, Tatematsu S, Kumagai H, Saruta T.
    Keio J Med; 2005 Jun; 54(2):102-8. PubMed ID: 16077260
    [Abstract] [Full Text] [Related]

  • 13. Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists.
    Massie BM, Lacourcière Y, Viskoper R, Woittiez A, Kobrin I.
    Am J Cardiol; 1997 Aug 21; 80(4B):27C-33C. PubMed ID: 9286851
    [Abstract] [Full Text] [Related]

  • 14. Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists.
    Davies GJ, Tzivoni D, Kobrin I.
    Am J Cardiol; 1997 Aug 21; 80(4B):34C-39C. PubMed ID: 9286852
    [Abstract] [Full Text] [Related]

  • 15. Calcium antagonist inhibits glomerular cell apoptosis and injuries of L-NAME exacerbated nephrosclerosis in SHR.
    Watanabe S, Ono H, Ishimitsu T, Matsuoka H, Ono Y, Fujimori T.
    Hypertens Res; 2000 Nov 21; 23(6):683-91. PubMed ID: 11131282
    [Abstract] [Full Text] [Related]

  • 16. Renoprotective effects of omapatrilat are mediated partially by bradykinin.
    Zhou X, Ono H, Ono Y, Frohlich ED.
    Am J Nephrol; 2003 Nov 21; 23(4):214-21. PubMed ID: 12789027
    [Abstract] [Full Text] [Related]

  • 17. Nitric oxide synthase inhibition in spontaneously hypertensive rats. Systemic, renal, and glomerular hemodynamics.
    Ono H, Ono Y, Frohlich ED.
    Hypertension; 1995 Aug 21; 26(2):249-55. PubMed ID: 7543452
    [Abstract] [Full Text] [Related]

  • 18. Comparison of L-type and mixed L- and T-type calcium channel blockers on kidney injury caused by deoxycorticosterone-salt hypertension in rats.
    Baylis C, Qiu C, Engels K.
    Am J Kidney Dis; 2001 Dec 21; 38(6):1292-7. PubMed ID: 11728963
    [Abstract] [Full Text] [Related]

  • 19. Effect of short-term treatment of SHR with the novel calcium channel antagonist mibefradil on function of small arteries.
    Li JS, Schiffrin EL.
    Am J Hypertens; 1997 Jan 21; 10(1):94-100. PubMed ID: 9008253
    [Abstract] [Full Text] [Related]

  • 20. Effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist, and an endothelin receptor antagonist on renal afferent arteriolar structure.
    Skov K, Fenger-Grøn J, Mulvany MJ.
    Hypertension; 1996 Sep 21; 28(3):464-71. PubMed ID: 8794834
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.